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Course and resolution of the coagulopathy in nephrotic children. Blood
coagulation function was serially studied in 84 children with nephrotic
syndrome. Fifty-eight had minimal change disease, six had focal
glomeruloscierosis and 20 had other forms of renal disease associated
with the nephrotic syndrome. Qualitatively similar abnormalities in
fibrinogen metabolism were present in all groups with clinically overt
nephrotic syndrome; plasma fibrinogen concentration and high molec-
ular weight fibrin(ogen) complexes (HMWFC) were grossly elevated (P
< 0.001 in most groups). With disease remission librinogen and
HMWFC concentrations decreased to the normal range, usually with
concomitant transient increase in plasma fibrinolytic activity (P < 0.02).
Alterations in concentrations of other proteins involved in coagulation
and fibrinolysis differed depending on the underlying cause for the
nephrotic syndrome. Antithrombin Ill concentration was normal ex-
cept in the focal glomerulosclerosis group. The results demonstrate that
a coagulopathy characterized by pathological degree of thrombin action
on fibrinogen complicates the nephrotic state and may be initiated by
different mechanisms. It is suggested that this coagulopathy, which
remits with clinical improvement, is consequent upon local intrarenal
activation of the blood coagulation system.
The association between the nephrotic syndrome and throm-
boembolic complications is well established. Although renal
vein thrombosis has attracted special attention, other lesions,
particularly venous thromboses and pulmonary embolism, oc-
cur with a higher frequency in nephrotic subjects than in the
general population [I]. Many investigators have attributed these
phenomena to alterations in the blood coagulation and plasma
librinolytic enzyme systems resulting in blood hypercoagulabil-
ity. The evidence has been indirect and mainly based upon
altered plasma concentrations of zymogens in the blood coag-
ulation cascade (factors VII, IX, XII and XIII), of accessory
factors (factors V and VIII), of components of the fibrinolytic
enzyme system (plasminogen and plasminogen activator) or of
inhibitors of blood coagulation and fibrinolysis (antithrombin
III, a2-macroglobulin, a1-antitrypsin and a2-antiplasmin). Other
changes include increases in plasma fibrinogen levels, platelet
counts and platelet aggregation. As summarized elsewhere
[1—3], the major findings include increased concentrations of
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factors V, VIII, XIII, protein C and a2-macroglobulin with
deficiencies in factors IX, XI and XII and antithrombin HI
although results have varied in individual studies. These abnor-
malities tended to revert towards normal with clinical remission
of the nephrotic syndrome.
More direct evidence for intravascular fibrin formation, such
as measurement of the products of fibrinogen—to—fibrin conver-
sion, have been lacking, however. The present investigation has
attempted to rectify this deficiency and has studied serially
throughout their clinical course, a group of children who had a
nephrotic syndrome due to well-defined renal pathologies.
Plasma fibrinogen chromatography was the principal method
used to study the blood coagulation and plasma—fibrinolytic
enzyme system. This technique detects the heterogeneity of
plasma "fibrinogen" consequent on clotting, fibrin deposition,
fibrinolysis and fibrinogenolysis [4—6]. 'I'he procedure quantifies
plasma fibrinogen and its derivatives which are classified into
(a) derivatives of fibrin(ogen) of larger molecular weight than
the native molecule (HMWFC); these are derivatives resulting
primarily from thrombin action and constitute either fibrinogen
in the process of polymerization or lyzed fibrin; (b) native
fibrinogen; and (c) moieties of smaller molecular weight than
fibrinogen (LMWD) which are proteolytic derivatives of fibrin-
ogen or fibrin. Substantial clinical investigative data have
documented the validity and utility of these assay procedures in
the study of thromboembolic disease complications and in renal
disease [6, 7]. These methods were supplemented by additional
studies of the coagulation/thrombolytic system.
Methods
Patient population
Studies were performed on 84 children whose ages ranged
from two to 14 years with a mean of 5.6 years. Each had
nephrotic syndrome defined by the usual criteria [8]. Of these,
58 presented with the clinical features of minimal—change
nephrotic syndrome of childhood (MCNS) [8, 9]. All were
steroid responsive but 52 subsequently had one or more re-
lapses of their disease. Although all of these 52 patients
behaved clinically as though they had MCNS [8, 9], each
underwent a renal biopsy as part of their clinical management.
The renal tissue was prepared for light, immunofluorescent and
electron microscopy using standard methodology [10]. In 26 of
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the patients, the renal biopsy confirmed the diagnosis of clas-
sical MCNS, but in 19 other biopsies there was some focal
glomerular hypercellularity, and in a further seven there was
slight glomerular deposition of immunoglobulins, primarily
1gM. The pathologist interpreted these additional histologic
abnormalities as being diagnostically insignificant.
Disease activity in patients with MCNS was staged as fol-
lows:
Stage I. Initial presentation or relapse of nephrotic syn-
drome, before steroid therapy began.
Stage II. As Stage I but 24 hours or later after initiation of
steroid therapy; patients had not yet diuresed, proteinuria
persisted, blood chemistries unchanged from those obtained at
the time of presentation.
Stage III. Early response to steroids; diuresis had occurred
and urine was protein—free; serum albumin was 2.5 g/dl or less
and serum cholesterol was 250 mgldl or more.
Stage IV. Late remission; patient still receiving steroids;
urine protein free, serum albumin >2.5 g/dl, serum cholesterol
<250 mg/dl.
Stage V. Complete remission, off therapy.
Of the 58 patients who presented with MCNS, 29 were
studied in Stage I, 15 in Stage II, 13 in Stage III, 23 in Stage IV,
and nine in Stage V. Whenever possible, patients were studied
sequentially. Thus, 25 were evaluated in at least three stages of
their disease, II were studied in two disease stages, and 22 were
studied in only a single stage.
All of the patients were treated with dietary sodium and fluid
restriction during Stages I through III. None of the patients
received diuretics, albumin infusions, or drugs other than
prednisone.
The remaining 26 nephrotic patients had their renal disease
diagnosed by renal biopsy. Six had focal segmental glomerulo-
sclerosis (FGS), eight had membranoproliferative glomerulone-
phritis (MPGN), and the remaining 12 immune—complex
chronic glomerulonephritis 18, 91.
Again these patients were investigated serially. All patients
were studied when nephrotic but before any treatment was
begun. This was equivalent to Stage I in MCNS and is referred
to in Results as "nephrotic." Some of these patients showed
partial response to treatment with corticosteroids; typically
there was a reduction in the magnitude of proteinuria and some
improvement in plasma protein concentrations. Such patients
were categorized as "improved." In this stage they still re-
ceived corticosteroid therapy and manifested proteinuria, hy-
poproteinemia and hypercholesterolemia. Patients who were no
longer receiving corticosteroids and whose edema was con-
trolled by dietary restrictions, sometimes supplemented by
diuretics are referred to as "stable". Typically, they continued
to have proteinuria, but less severe hypoalbuminemia and
hypercholesterolemia.
Results from patients with nephrotic syndrome are compared
with findings from 54 normal children assayed over the same
time period. A group of six children, not acutely ill, with normal
plasma fibrinogen chromatographic findings being investigated
for other renal disease were used as "normal" in some assays.
The project received approval from the Human Studies
Committee of Washington University. Informed consent was
obtained before any subject was investigated.
Plasna studies
Plasma fibrinogen, plasminogen, plasma factor XIII, anti-
thrombin III (AT III), a2-macroglobulin and a1-antitrypsin
determinations were performed as described previously [7].
Fibrinopeptide A (FPA) assay was performed with radio-
immunoassay kits from Mallinckrodt, Inc. (St. Louis, Missouri,
USA). AT III activity was assayed with H-D-Phe-Pip-Arg-pNa
(S-2238) thrombin substrate by the method of Abildgaard, Lie
and Odegaard [11]. A plasma standard, consisting of pooled
plasma from clinically well adults was defined as having 100%
activity; the same plasma standard was used for all radial
immunodiffusion assays. The assay for a2-antiplasmin and
fibronectin was by Rocket immunoelectrophoresis [12].
Plasma fibrinogen chromatography was performed as previ-
ously described [6], but selected samples were also examined
by gel permeation chromatography on 90 x 2.5 cm BioGel 5 M
columns with a void volume of 145 ml [13]. The columns were
equilibrated and eluted with 0.06 M Tris pH 7.6 containing 0.3 M
NaCI and 10 mg/liter soybean trypsin inhibitor (Sigma Aldrich,
St. Louis, Missouri, USA). Flow—rate was approximately 15
mI/hr and 5 ml fractions collected. Eluate fractions were as-
sayed for fibrinogen antigen in a Technicon immuno-precipit-
ator (Technicon Corp., Terrytown, New York, USA) using goat
antiserum to human fibrinogen (Gateway Serum Company, St.
Louis, Missouri, USA), and for FPA after treatment with
thrombin 5 U/mI for 10 minutes. HMWFC, intact fibrinogen,
and LMWD concentration were calculated using a computer
program based on chromatographic plate theory [4].
Urine studies
Urine samples were assayed by the same techniques as the
plasma samples, that is, for fibrinogen, plasminogen, AT III,
cr1-antitrypsin, a2macroglobulin, cr2-antiplasmin antigens, and
for FPA with and without thrombin treatment. The minimum
detectable levels of fibrinogen was on the order of 1 sg/ml, AT
III, a2-antiplasmin and plasminogen 5 g/ml and a1-antitrypsin
and a2-macroglobulin 20 pg/ml. Samples with undetectable
levels are reported as zero. Urine chromatography was per-
formed on a 30 x 1 cm Sephadex G-l00 column equilibrated and
eluted with 0.05 M Tris, 0.1 M NaCI buffer pH 8.5 containing
0.1% ovalbumin. One ml urine or 0.5 ml concentrated urine,
with or without bentonite adsorption [14] was applied and 0.7
ml fractions collected; the flow rate was 15 mI/hr. Effluent
fractions were assayed for FPA, before and after thrombin
treatment, and for fibrinogen antigen.
Crossed unmunoelectrophoresis
Simultaneously obtained plasma and urine samples from two
patients with FGS were examined by crossed immunoelectro-
phoresis. The urine samples were dialyzed against distilled
water overnight, and concentrated to a fifth of their volume by
pervaporation. Agarose, 1%, dissolved in a 1:4 dilution of the
high resolution running buffer, was deposited as a 1.5 mm thick
film on Gel Bond film (agarose and film from Marine Colloids,
Rockland, Maine, USA); 1.5 mm diameter wells were punched
in the corner of each film and 5 tl samples placed in the wells.
Electrophoresis in the first dimension was for two hours at 3 m
amp per plate; the agarose film except the band with the
electrophoretically separated sample was removed and re-
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Table 1. Sequential plasma findings in children with minimal change nephrotic syndrome
Plasma fibrinogen
Stage of
disease
Number of
pts/samples'
Plasma
fibrinogen
chromatography a,-Macro-
globulin
. .
a,-Anti- Antithrom-
trypsin bin Ill
.Plasmin-
ogen
Factor
XIII(HMWFC) (LMWD)
mg/dl C/ of value in normal children U/mI
1 29/34
P'
462 25"
<0.001
79 10 154 14
<0.001 <0.001
145 12
<0.001
113 II 104 5
NS NS
98 3
NS
34 4
<0.05
II 15/16
P
394 19
<0.001
SI 9 172 22
<0.01 <0.001
161 24
<0.001
94 10 90 6
NS NS
III 10
NS
28 4
NS
11! 13/15
P
369 26
<0.02
44 6 141 22
<0.01 <0.001
140 10
<0.001
123 7 106 6
<0.05 NS
113 3
<0.05
28 2
NS
IV 23/24
P
248 14
NS
22 5 85 8
NS NS
139 12
<0.001
108 5 102 5
NS NS
109 8
NS
26 2
NS
V 9/12
P
250±17
NS
34±7 80±11
NS NS
92±15
NS
98±8 94±9
NS NS
93±9
NS
20±3
NS
Normal 54/54 298 14 24 3 69 23 100 5 100 5 100 3 100 4 26 I
children
The number of samples assayed refers to fibrinogen and fibrinogen chromatographic data but the majority of patients in all groups were also
assayed for the other plasma proteins.
"Mean SEM
Significance of difference from normal children.
placed with a similar agarose gel containing antiserum to
a2-antiplasmin, AT III (Nygaard, Oslo, Norway), a1-anti-
trypsin, plasminogen (Kallestad, Chaska, Minnesota, USA) or
fibrinogen (Gateway). Electrophoresis, transverse to the first
dimension, was overnight at 1 m amp per plate. The plates were
washed in 2% NaCI and two changes of distilled water (each
wash two hours) with continuous stirring, and stained with
amido schwartz.
Analysis of data
Standard statistical methods were employed. Deviation of
observations from the mean has been expressed throughout in
terms of the standard error. Student's t-test was used for
comparison of results between groups.
Results
Table I summarizes the blood coagulation and fibrinolysis
related findings in children with MCNS. Initial analysis of data
was made with children subdivided into three groups: a) those
with no histologic abnormality on renal biopsy plus those who
had only a single episode of steroid—responsive nephrotic
syndrome with all the typical clinical features of MCNS; b)
those with biopsy findings of mild mesangial hypercellularity;
and c) those with intraglomerular deposits of 1gM demonstrated
on renal biopsy. No significant intergroup differences were
detected. Since it is uncertain whether patients with intraglo-
merular deposition of 1gM should be considered to have
MCNS, this small group of subjects has been excluded in
subsequent analyses; the remaining two subgroups have been
combined as a single MCNS group in all tables.
The most striking differences between MCNS and normal
children are those related to fibrinogen metabolism and catab-
olism. In patients in relapse, studied before treatment was
begun (Stage I), plasma fibrinogen, HMWFC and LMWD were
markedly and significantly increased above normal levels. With
institution of steroid therapy, fibrinogen and HMWFC levels
started to fall, a decrease reaching statistical significance by
Stage III, so that by Stage IV the difference from normal was
not significant. LMWD levels, which relate to fibrinolysis,
increased in Stage II, fell during Stage III and were within the
normal range by Stage IV.
In addition, there were statistically significant increases in
plasma levels of a2-macroglobulin and Factor XIII in Stage I.
a2-Macroglobulin remained markedly elevated until Stage V. In
spite of suggestive trends, most differences in plasma concen-
trations of other proteins did not reach statistical significance.
Plasminogen was raised in Stages II and III, significantly
different from normal only in Stage III; a1-antitrypsin was
raised significantly during Stage III.
There are at least two mechanisms for production of
HMWFC. The primary, direct action of thrombin on fibrinogen,
leads to release of fibrinopeptide A (FPA) and formation of
fibrin(ogen) dimer, trimer or other polymers, which regardless
of molecular size contain two molecules of FPA per molecule
[13]. The second mechanism, that of plasmin action on fibrin,
yields large molecular weight fibnn breakdown products that
contain no FPA. These two mechanisms can be distinguished
by determining the ratio of thrombin releasable FPA to fi-
brinogen antigen in fibrinogen/fibrin derivatives.
That both mechanisms occur in the MCNS patients is illus-
trated in Figure 1. Figure IA shows the findings in a Stage I
patient who had a fibrinogen level of 875 mgldl. The solid line
shows the elution pattern of fibrinogen antigen. This clearly
shows at least three components. Peak "a" contains HMWFC
which have a larger molecular weight than fibrinogen, peak "b"
contains molecules with a size equal to native fibrinogen, and
peak "c" consists of LMWD which have a molecular radius
lower than fibnnogen. The stippled lines in Figure 1 show FPA
content after thrombin treatment of the fractions following
elution. By comparing the ratio between fibrinogen antigen
concentration and FPA levels of the three peaks, it is possible
to determine the derivation of the fibrinogen antigenic material
in the plasma sample. The FPA content relative to that of
fibnnogen antigen in peak "a" is almost one—half that of peak
"b". Since the component(s) in peak "a" contain FPA and are
of considerably larger molecular weight than fibrinogen, they
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Fig. 1. Plasma fibrinogen chromatographic findings during three
MCNS disease stages. Top section shows findings in a Stage 1 patient,
middle section those in a Stage II patient, and bottom those from a
patient in remission (Stage V). The left hand ordinates are fibrinogen
antigen concentrations (•) the right hand ordinates fibrino-peptide A
content (0) and the abscissa chromatographic effluent volumes.
consist of dimers/polymers of fibrinogen, that is, fibrinogen in
the process of clot formation. Peak "c" consists of breakdown
products smaller in size than native fibrinogen. They have been
derived from both fibrin and fibrinogen. If they were all derived
from fibrin, they would not contain any FPA; if they were all
derived from fibrinogen, their relative FPA content would be
higher than that observed.
Figure 1B, which shows the findings in a Stage III patient
who had a plasma fibrinogen concentration of 390 mg/dl,
demonstrates that the fibrinogen antigen in this patient is also
inhomogeneous. That eluted (region "d") before fibrinogen is
interpreted as consisting mainly of fibrin breakdown products
since it contained little FPA. At this stage, the major coagula-
tion abnormality in this patient was degradation of previously
formed fibrin. The bottom panel shows the elution pattern of a
Stage V patient who had a fibrinogen level of 290 mgldl. Results
were comparable to those observed from normal subjects,
confirming the data shown in Table 1 which indicate that the
coagulation abnormalities in this patient had reversed. These
examples were chosen because the components are apparent by
visual inspection. Elution patterns, however, typically show
frequent complex mixtures of the different components and can
only be resolved by computer analysis of the fibrinogen antigen
and FPA curves.
The results from children with nephrotic syndrome second-
ary to FGS or to glomerulonephritis (GN) are shown in Table 2.
Prior to treatment, both of these groups of children had signif-
icant elevations of plasma fibrinogen concentrations. Levels in
the FGS patients were comparable to those seen in MCNS;
values in children with GN were elevated above normal (P <
0.001) but the increases were significantly less than those
observed in either MCNS (P < 0.005) or in FGS (P = 0.01).
Both the FGS and GN patients had significantly increased
plasma levels of both HMWFC and LMWD, comparable to
those observed in the Stage I MCNS patients. In the FGS
patients, plasma levels of both a2-macroglobulin (P < 0.001)
and Factor XIII (P < 0.02) were increased and levels of AT III
(P < 0.02) were decreased significantly from normal; the value
for a1-antitrypsin was decreased but not significantly.
A different pattern of abnormalities was observed in GN.
Values for a2-macroglobulin and Factor XIII were not in-
creased significantly, nor were the levels of AT III decreased.
In contrast, a1-antitrypsin was increased from normal (P <
0.02) whereas it was reduced in FGS. Comparing the results
from the FGS patients with those from the GN patients, the
differences in fibrinogen levels (P <0.01), in a2-macroglobulin
(P < 0.001), in a-antitrypsin (P < 0.01) and in antithrombin III
(P < 0.01) were all of statistical significance.
Only two of the FGS patients showed any improvement
following treatment, the remaining four progressed to end—stage
renal failure. Results from these two patients did not differ from
those in ON patients and have been combined in Table 2. In the
"improving" stage each of the abnormalities that was observed
in the patients pre-treatment reverted towards normal. The only
significant abnormality that persisted was the elevation of
a1-antitrypsin. In the "stable" phase none of the values differed
significantly from those observed in normal children.
Table 3 shows findings for paired plasma and urine samples
for three patients with Stage I MCNS and for three with FGS
prior to receiving treatment. Because of the difficulties in
obtaining accurately timed urine collections in nephrotic chil-
dren who are markedly oliguric, all urinary values are ex-
pressed per mg urine creatinine, rather than per unit of time. All
of the patients had elevated plasma fibrinogen values. Each of
the MCNS patients showed mild increases in urinary fibrinogen
antigen as did one of the FGS patients. The remaining two FGS
patients had grossly increased urinary—excretion of fibrinogen
antigen. Plasma and urinary FPA concentrations were substan-
tially increased in the FGS patients. Plasma FPA assays were
not performed in the MCNS patients but urinary FPA values
were normal in two of the urines and notably increased in one.
Plasma plasminogen levels tended to be depressed in the FGS
patients, and plasminogen was detected in the urine of those
patients but not in that of the MCNS subjects. Similarly,
a2-antiplasmin was found only in the urine from the FGS
patients and their plasma levels tended to be lower than those in
the MCNS patients. In contrast, a1-antitrypsin was present in
160 200 240 280
Effluent volume, ml
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Table 2. Plasma findings at various disease stages in children with nephrotic syndrome secondary to focal segmental glomerulosclerosis or to
glomerulonephritis
Plasma fibrinogen
chromatography . .Plasma a,-Macro- a1-Anti- Antithrom-
fibrinogen (HMWFC) (LMWD) globulin trypsin bin 111Patient Number of
group pts/samplesa mg/dl % of value in normal children
.Plasmin-
ogen
Factor
XII!
U/mI
Nephrotic
FGS 6/18 455±38 79±8 128±12 232±13 85±6 79±6 90±10 34±3
P <0.001 <0.001 <0.001 <0.001 NS <0.02 NS <0.02
GNb 21/52 355±16 64±5 123±11 113±11 125±9 98±4 96±4 25±3
P <0.01 <0.001 <0.001 NS <0.02 NS NS NS
Improving 17/35 280 16 31 4 85 6 102 8 125 7 103 4 96 4 27 2
P NS NS NS NS <0.02 NS NS NS
Stable 11/17 270 16 22 7 79 13 82 5 118 14 101 6 100 5 32 8
P NS NS NS NS NS NS NS NS
Normal 54/54 298 14 24 3 69 23 100 5 100 5 100 3 100 4 26 I
children
See Table I for footnotes
b Includes patients with MPGN and with other forms of chronic glomerulonephritis
Table 3. Paired plasma and urine findings in patients with MCNS or FGS before treatment
MCNS RS
Pt I Pt 2 Pt 3 Pt I Pt 2 Pt 3 Normal
Fibrinogen
Plasma mg/mI 4.6 8.8 4.6 6.6 4.1 5.6 3 0.1
Urine pg/mg creat. 3.2 2.0 9.2 2152 757 7.5 0
Fibrinopeptide A
Plasma ng/ml — — — 4.1 3.4 4.6 <2
Urine ng/mg creat. 2.8 237 31 519 163 360 <2
Plasminogen
Plasma tg/mI 130 145 125 90 70 70 110 5
Urine /ig/mg creat. 0 tr 0 153 160 17 0
a-Antiplasmin
Plasma zgJmI 76 70 133 33 38 47 63 5
Urine .tg/mI creat. 0 0 0 20 14 11 0
n1-Antitrypsin
Plasma mg/mi 2.5 3.9 2.4 3.4 1.8 1.6 3 0.2
Urine mg/mg creat. 0.5 0.5 0.3 0.4 0.7 0.5 0
Antithrombin II!
Plasma tg/mI 204 204 370 132 139 140 24(1 7
Urine pg/mg creat. 0 162 0 300 243 98 0
comparable concentrations in all the urine samples studied and
AT III in all the FGS samples but in only one MCNS sample;
plasma AT III levels were lower in the FGS than in the MCNS
patients. These observations suggest that while MCNS patients
show selective proteinuria, selectivity for blood coagulation
and plasma fibrinolytic enzyme system is incomplete.
Urine from an FGS patient, which contained FPA and
fibrinogen antigen in the form of fibrinogen proteolysis prod-
ucts, and FPA was chromatographed on a Sephadex G-lOO
column both before and after bentonite adsorption. The effluent
fractions were assayed for FPA before and after thrombin
treatment; Figure 2 illustrates the non-adsorbed sample. Fibrin-
ogen proteoiysis products were eluted in two peaks; the peak
close to the void volume was absent in the bentonite adsorbed
sample. Prior to thrombin treatment of the effluents, FPA was
assayable only in the position of the second peak which is in the
elution zone of I'25-labeled FPA. With thrombin treatment of
the eluate, FPA was assayable in eluates from the larger
fibrinogen product peak. Thus this urine sample contained free
FPA as well as fibrinogen proteolysis products which release
FPA when exposed to thrombin.
Crossed immunoelectrophoretic studies of paired plasma and
urines from an FGS patient are shown in Figure 3. a1-
Antitrypsin, a2-Antiplasmin and AT III antibodies were used in
the second dimension. The findings demonstrate that these
plasma proteins were excreted in degraded form or were
degraded in the urine. In each case the plasma protein migrated
as a single peak, while the urinary proteins were inhomogenous
and only a minor portion migrated with the same mobility as the
plasma protein. Similar findings, not illustrated, were observed
for plasma and urine plasminogen assays. These data suggest
that activity assay for specific plasma components in the urine
may considerably underestimate the total rates of urinary
excretion.
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Fig. 2. Sephadex G-IOO chromatography of untreated urine from a
patient with focal glomerulosclerosis. The left hand ordinate is FPA
concentration (0), the right hand ordinate is fibrinogen antigen concen-
tration expressed in fibrinogen equivalents (A) and the abscissa effluent
volume. FPA was determined after thrombin treatment of effluent
fractions. Without thrombin treatment or after bentonite absorption
only the second FPA peak which is eluted in the position of F25-FPA
was present.
Discussion
Thrombo-embolic vascular disease complications of ne-
phrotic syndrome occur most frequently in adult patients with
membranous glomerulopathy but have been described also in
children with a variety of causes for their nephrotic syndrome
including MCNS [1—3, 8, 91. Only one of our patients had a
clinically apparent vascular thrombosis—an MCNS patient had
occlusion of an axillary vein—a venous thrombosis was sus-
pected but not proven in one additional patient. Despite this the
majority of the subjects had laboratory evidence for increased
intravascular fibrin formation.
Previous laboratory evidence for the predisposition to devel-
opment of thrombosis in nephrotic syndrome has been derived
primarily from studies demonstrating altered concentration of
blood coagulation factors and inhibitors [1—3, 15, 161. Increases
in factors V, VIII, XIII, fibrinogen, platelet count and altered
platelet reactivity together with decreases in AT III, plasmino-
gen and plasminogen activator could theoretically predispose to
thrombosis. However, these alterations in blood coagulation
and plasma fibrinolytic enzyme—components are inconsistent
and often of minor degree. Thus, only tenuous evidence links
these coagulation anomalies with predisposition to thrombosis:
anomalies which, though possibly of secondary importance in
the severely afflicted patient, are unlikely to be of primary
etiologic significance in the hypercoaguable state.
These alterations in specific blood factor concentrations have
been explained as being due to renal excretion of coagulation
components (Table 3) [17—21]. Kauffman et al 1181 suggested
that thrombosis in patients with nephrotic syndrome may be
analogous to that observed in congenital deficiency of AT III
and be caused by the low AT III concentrations observed in
some nephrotic patients. Our data and those of others [16], do
40
. not support this view; also, other inhibitors of thrombin action,
such as a2-macroglobulin [22] and protein C [23, 24] are present
in considerable excess and may compensate for the reduction
30 in AT III. A second explanation is that the increased concen-trations of some of the coagulation factors results from a
generalized increase in protein synthesis contingent upon hy-
poalbuminemia [25, 26]. Alternatively there is both animal
20 experimental [27] and clinical investigative evidence [28] dem-
onstrating that intravascular thrombin formation could itself
induce secondary changes in coagulation component concen-
trations similar to those reported here.
10 Biochemical evidence for increased intravascular fibrin for-
mation rests on the demonstration of high molecular weight
fibrinogen—derived moieties, which result from either thrombin
action on fibrinogen or from plasmin action on fibrin. Distinc-
tion between these two mechanisms can be made by determi-
nation of FPA content of the complexes. HMWFC derived from
plasmin action on fibrin contain no FPA while those resulting
from thrombin action on fibrinogen, that is, polymerizing fibrin,
contain 2 M FPAIM [13]. The complexes eluted before the major
fibrinogen peak (Fig. IA) are characteristic of fibrin(ogen) dimer
of molecular weight 650,000 containing two residual molecules
of FPA [13], while the shoulder on the ascending major fibrin-
ogen peak (Fig. 1B) contains little, if any, FPA and thus is
characteristic of lysed fibrin. These findings demonstrate the
existence of fibrin formation during the acute phase and the
pathophysiologic significance of this finding is confirmed by the
demonstration of lysed fibrin in the plasma during the recovery
phase. By further development of the FPA/fibrinogen antigen
ratio approach, it has been shown that the LMWD fractions in
both normal subjects and in patients with enhanced fibrinogen
turnover are composed both of fibrinogen proteolysis products
and lysed fibrin [5]. Thus elevations of LMWD fractions in the
nephrotic patient is due to both increased fibrinolysis and
fibrinogenolysis (Fig. I).
The findings in the MCNS patients clearly establish the
correlation between intravascular fibrin formation and disease
activity with normalization of fibrin formation following disease
remission. With disease relapse, HMWFC increase was statis-
tically highly significant (P < 0.001) and the fibrinogen level was
substantially elevated. Initially therapy resulted in decrease in
HMWFC and fibrinogen levels, even in the presence of protein-
uria and hypoalbuminemia, though both moieties remained
significantly elevated (P < 0.05 and P < 0.001, respectively).
With disease remission these findings gradually normalized.
The early stage of clinical improvement was associated with
increased fibrinolytic activity. Similar sequential findings of
elevated HMWFC followed by elevated fibrin(ogen) breakdown
products (LMWD) before return to normal were also seen in
children with acute post-streptococcal glomerulonephritis [7]
and in patients with acute crescentic glomerulonephritis [29]. In
contrast, patients with FGS showed both elevated plasma
fibrinogen and HMWFC through their disease course while they
were nephrotic, suggesting a continuing process of intravascu-
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Fig. 3. Crossed immunoelectrophoretic studies of plasma and urine from a patient with focal gloineruloscierosis. Antithrombin LII (A),
a2-antiplasmin (B) and a1-antitrypsin (C) antisera were used in the second dimension. In each the plasma (top) showed a homogeneous peak, while
the corresponding urine sample (below) showed inhomogeneity and altered electrophoretic mobility.
lar fibrin formation; only two of these patients eventually
improved.
The pathophysiologic significance of the plasma fibrinogen
chromatographic data is supported by FPA plasma findings.
Tomura et a! [30] showed increased plasma concentrations of
FPA and of B /315-42 in patients with a variety of renal diseases
including MCNS and FGS. B /315-42 is the amino acid sequence
of the fibrinogen /3-chain after fibrinopeptide B has been re-
leased, that is, a fibrinolytic breakdown product of fibrin. In our
study the plasma FPA concentration in FGS patients was
greater than normal, 2 to 8 ng/ml (Table 3 and other data not
shown) and urinary FPA was grossly elevated. The major
portion of FPA in the urines from the FGS patients was free
FPA, but these samples also contained fibrin(ogen) proteolysis
products, a portion of which released FPA on thrombin treat-
ment. In general, plasma concentration of FPA and its urinary
excretion are correlated [14]. However, fibrinogen or fibrinogen
derived moeities in urine may release FPA so that the urinary
FPA content is much greater than expected on the basis of the
plasma concentration as shown by the FGS patients and one of
the MCNS patients (Table 3). Figure 2 illustrates fibrinogen
breakdown products which release FPA after thrombin treat-
ment.
Though our biochemical data demonstrate excess fibrin for-
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mation and fibrinolysis during active nephrotic syndrome with
compensatory fibrinolysis during the disease recovery phase,
the anatomic site(s) involved in these phenomena are unclear.
Several investigators [31] have studied MCNS renal biopsy
material for intraglomerular fibrin and adherent platelet depos-
its. The results of these studies would be influenced by the
examination technique used and, more importantly, by the time
of renal biopsy. Generally they found small amounts of intra-
glomerular fibrin in a variable proportion of patients, some-
times, but relatively infrequently, in association with platelet
deposition. For example, Duffy et al [32] found intraglomerular
fibrin in 10 of 18 biopsies from cases with clinically active
MCNS and platelet aggregates in eight of these biopsies. These
findings were generally absent in biopsy material taken during
remission. Demonstration of intraglomerular fibrin deposition
even when this process is extreme, is likely to be difficult since
fibrin deposition is transient and dynamic and, as demonstrated
by our data, accompanied by simultaneous and subsequent
fibrinolysis. Moreover, the kidney produces two powerful
plasminogen activators, single and double chain urokinase,
which may also contaminate renal biopsy material.
Indirect evidence suggests that the primary defect in MCNS
could involve the immune system and that the clinical manifes-
tations of the disease could be the result of neutralization of
negative charge sites in the glomeruli and at other sites [8, 33].
Indeed, many of the features of MCNS can be reproduced in
animals by neutralizing charge sites with polycations [34, 351.
Recent observations indicate that platelets may be involved in
this process since their negative charge sites are reduced in
MCNS relapse [36, 37]. Such a change could precipitate the
coagulation cascade. If, however, this change in platelet charge
is unique to MCNS, as the recent data suggest [36], it would not
explain the coagulopathy observed in our patients with the
nephrotic syndrome secondary to chronic glomerulonephritis
(GN). Other pathologic changes occur in GN that could precip-
itate intraglomerular fibrin deposition. Indeed it is of interest
that although patients with MCNS, FGS and GN all had
alterations in fibrinogen metabolism, the changes in concentra-
tion of other proteins involved in coagulation and fibrinolysis
were different in patients with GN compared to those with
MCNS and FGS (Tables 1, 2). The lipid abnormalities charac-
teristic of the nephrotic syndrome [9] also could influence
coagulation function.
The coagulopathy in MCNS develops independently of ste-
roid administration. Significant abnormalities in the coagulation
system were consistently present before treatment with steroids
was begun. However, the administration of these drugs could
provide an additional risk factor for thromboembolic complica-
tions in nephrotic syndrome as could venous stasis secondary
to bed rest or the presence of edema. Our earlier studies [7, 29]
indicated that in post-streptococcal glomerulonephritis,
intraglomerular fibrin deposition may contribute to depressed
renal function in the acute phase of the disease. In this
self—limiting disease, the abnormal blood coagulation findings
reverted to normal with clinical improvement and there was
concomitant evidence of fibrinolysis. Conversely, in severe
crescentic glomerulonephritis, coagulation anomalies persisted
and the data were compatible with the thesis that intrarenal
fibrin deposition predisposed to glomerulosclerosis [29]. Possi-
bly long continued intrarenal fibrin deposition in patients with
nephrotic syndrome, including some with apparent MCNS
may, as in patients with severe crescentic glomerulonephritis,
predispose to glomerulosclerosis of the focal type. The
coagulopathy reversed with response to treatment in patients
with MCNS, an entity with a good prognosis, but persisted in
patients in whom there was no response to treatment and who
remained nephrotic.
The present study suggests that the previously reported
conflicting data of markedly different plasma levels of coagula-
tion factors in the nephrotic syndrome may be the consequence
of differences in the disease being studied or in the disease stage
(Tables I and 2). Finally, since the coagulopathy in MCNS
patients develops concomitantly with disease onset or clinical
relapse, in the absence of significant change in coagula-
tion/fibrinolytic enzyme components or their inhibitors, our
data suggest that coagulopathy is integral to the primary renal
disease pathology.
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